INSP Inspire Medical Systems, Inc.

Inspire Medical Systems has seen its share price fall sharply over several years, and that slide raises a pointed question about whether the current market value still lines up with the cash the business is expected to generate. With the stock now well below past peaks, the key issue is how today’s US$69.36 price compares with its future cash flow profile. The share price decline of 71.2% over 5 years puts long term expectations for Inspire Medical Systems’ cash generation under the...

Inspire Medical Systems (INSP) has been drawing attention after a sharp move in its share price, with the stock last closing at US$70. That shift is prompting fresh questions about how investors are treating this sleep apnea specialist. Recent trading tells a mixed story for Inspire Medical Systems. The share price has surged with a 56.9% 90 day return and 13.9% 1 month gain; yet momentum is fading near term with the 7 day share price return down 7.6% and the year to date share price return...

Stryker's sales have grown about 10% a year on average over the past three years, and so have ResMed's. That shared growth rate in medical devices is the bet the two have in common. Stryker (SYK) is the giant, selling hospitals everything from hip and knee products to capital equipment. ResMed is a sleep device maker with less than a quarter of Stryker's revenue. Stryker costs 32.6 times its past year's earnings, against 21.9 times for ResMed. So does Stryker's reach justify that higher price? T

Inspire Medical is navigating a major product transition as clinical evidence, patient access efforts and reimbursement progress support growth prospects.

DGX study finds nearly one-third of Lyme-seropositive patients had antibodies to another tick-borne pathogen, highlighting broader testing needs.

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.

OPKO Health is gaining on pharmaceutical growth, a broad clinical pipeline, strategic partnerships and fresh non-dilutive financing.

WAT launches the BD FACSDiscover A7 globally, bringing advanced spectral flow cytometry, automation and standardized workflows to research labs.

West Pharmaceutical's biologics exposure, Annex 1 projects and delivery-device growth support prospects despite near-term headwinds.

XRAY's digital dentistry, R&D and restructuring support growth, but CAD/CAM, implants, SureSmile and tariff pressures pose near-term risks.

SYK expands its Foot & Ankle portfolio with Prophecy for Incompass and smartHEX, linking planning, implants and limb reconstruction.

CONMED's BioBrace and AirSeal platforms, robotic growth and easing supply bottlenecks support its long-term outlook despite tariff headwinds.

GE HealthCare launches an AI-powered SaaS tool that predicts hospital capacity challenges up to 72 hours ahead and recommends actions to ease bottlenecks.

Inspire Medical Systems has seen its share price move sharply over several timeframes, which naturally puts the focus on whether the current valuation is supported by the cash it can generate. With the stock price at US$74.32 at the last close, the key issue now is how that market tag lines up with the business’s future cash flows. Over the past 5 years, Inspire Medical Systems shares have fallen 70.2%, which puts a lot of weight on whether the underlying cash flow story still backs the...

Medical Systems, American Well and Butterfly Network have been highlighted in this Industry Outlook article.

Shares of medical technology company Inspire Medical Systems (NYSE:INSP) jumped 7.4% in the morning session after Stifel analyst Jonathan Block raised the price target on the company to $80.00 from $75.00 while maintaining a Buy rating.

INSP, AMWL and BFLY are positioned to gain from digital health and AI demand despite cybersecurity risks.

Inspire Medical Systems currently trades at $62.14 per share and has shown little upside over the past six months, posting a small loss of 3.4%. The stock also fell short of the S&P 500’s 11.7% gain during that period.

Inspire (INSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

Inspire Medical stock's 39.7% three-month surge is driven by the easing of reimbursement pressures, increasing Inspire V adoption and Project Horizon targeting longer-term expansion.

Inspire Medical's Inspire V adoption, clinical evidence and underpenetrated OSA market support growth despite coding and reimbursement headwinds.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 27.5% over the past six months, topping the S&P 500 by 16.2 percentage points.

ALGT, HMC, INSP, AII and ALL have been added to the Zacks Rank #1 (Strong Buy) List on August 18, 2026.

Inspire Medical Systems stock has had a difficult run over the past three years, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading at a discount to their estimated worth. Shareholders have seen the stock decline 73.6% over the past three years, which puts the current valuation in sharp focus for anyone still holding or looking at the company fresh. The recent announcement of a new growth plan, alongside higher revenue...

The market may be focused on temporary hurdles, but a strategic acquirer would see a unique technology at a strong price.

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.

Inspire Medical Systems’ second quarter results were marked by improved coding clarity and cost discipline, which management credited as key drivers behind the company’s outperformance versus Wall Street expectations. Despite a year-on-year revenue decline, CEO Tim Herbert pointed to effective navigation of the evolving reimbursement landscape as a critical factor, stating the company delivered “adjusted operating income and positive cash flow ahead of expectations through continued disciplined

INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.

Revenue fell 7.6% on coding disruptions, but management raised full-year guidance.

HIMS' second-quarter 2026 results are likely to benefit from weight-loss demand and global expansion even as margin pressures and higher spending linger.

Inspire Medical raised its 2026 outlook after a Q2 beat, as Inspire V mix and cost control offset weak U.S. procedure activity.

Inspire Medical's vast sleep apnea opportunity, rising margins and debt-free balance sheet support patience as reimbursement issues weigh on procedures.

Inspire Medical shares jumped 28.1% as an earnings beat, raised 2026 guidance and estimate revisions offset reimbursement pressure.

INSP beats second-quarter estimates, raises its 2026 outlook and sees shares jump despite U.S. reimbursement pressures and lower revenues.

Walmart downgraded, Palantir upgraded: Wall Street's top analyst calls

Moby summary of Inspire Medical Systems, Inc.'s Q2 2026 earnings call

Why Inspire Medical Systems stock moved on Q2 earnings and guidance Inspire Medical Systems (INSP) caught investor attention after Q2 results that topped revenue and earnings expectations despite a year over year decline tied to coding and reimbursement disruptions. The company raised its full year revenue and EPS guidance and introduced Project Horizon, a restructuring plan designed to free up about US$30 million for growth investment. The market responded positively to management’s...

Inspire Medical Systems recently appointed AtriCure CEO Michael H. Carrel to its Board and committees, while long-serving director Casey M. Tansey plans to retire, as the company reported quarterly revenue of US$200.58 million and earnings of US$0.14 per share that exceeded analyst expectations despite a year-on-year decline. Alongside these governance changes, Inspire raised its full-year outlook and launched Project Horizon, aimed at unlocking US$30 million in annualized investment...

Despite a 7.6% revenue decline from coding disruptions, the company raises its full-year outlook and unveils Project Horizon to drive future growth.

Inspire Medical Systems (NYSE:INSP) reported second-quarter revenue of $200.6 million, down 7.6% from a year earlier, as coding and reimbursement disruptions continued to affect procedure volumes. The company said results exceeded its internal expectations for profitability and cash flow, prompting

The headline numbers for Inspire (INSP) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Inspire (INSP) delivered earnings and revenue surprises of +163.64% and +2.95%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Medical technology company Inspire Medical Systems (NYSE:INSP) reported Q2 CY2026 results exceeding the market’s revenue expectations, but sales fell by 7.6% year on year to $200.6 million. The company’s full-year revenue guidance of $855 million at the midpoint came in 1.4% above analysts’ estimates. Its non-GAAP profit of $0.14 per share was significantly above analysts’ consensus estimates.

Medical technology company Inspire Medical Systems (NYSE:INSP) will be announcing earnings results this Monday after the bell. Here’s what to expect.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Butterfly Network (BFLY) delivered earnings and revenue surprises of +66.67% and +14.83%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Investing.com -- UBS initiated coverage on four U.S. medical technology companies on Monday, taking a bullish stance on robotic surgery specialist Intuitive Surgical and orthopedic products maker Enovis, while adopting a more cautious outlook on sleep apnea device manufacturer Inspire Medical Systems and a neutral view on Integra LifeSciences.

Globus Medical, Inspire Medical Systems, and Penumbra show varied revenue growth and analyst ratings, offering medical device investors alternatives to traditional pharmaceutical stocks.